Screener
Immunovant, Inc. IMVT Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Net loss per common share — basic and diluted | $(2.77) | $(2.73) | $(1.88) |
| Weighted average common shares outstanding — basic and diluted | 182,421,233 | 151,573,553 | 138,100,577 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s net income?
- Immunovant, Inc. (IMVT) reported net income of -$147.86M in Q1 2026.
- How has Immunovant, Inc.'s net income changed year-over-year?
- Immunovant, Inc.'s net income decreased by 38.9% year-over-year, from -$106.45M to -$147.86M.
- What is the long-term trend for Immunovant, Inc.'s net income?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s net income has grown at a 34.0% compound annual growth rate (CAGR), from -$156.73M to -$505.61M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Immunovant, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude